TransCode Therapeutics, Inc.
RNAZ
Last
$1.86
Day
+8.8%
1y
-85.5%
5y
-100.0%
52w
-91.9%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1334d
EMA 21
1.82
EMA 50
2.69
EMA 200
160.32
20d high
-28.5%
5y high
-100.0%
5y range
0th
Positions held
Your positionsRNAZ isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$2.07
Stop
$1.41
Stop distance
24.2%
Target vs last
+11.3%
Fundamentals
| Market cap | $28.95M | Enterprise value | $187.27M | Trailing P/E | — | Forward P/E | -2.85 |
| PEG | — | Price / book | -0.06 | Beta | 1.26 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -59.3% | ROA | -19.9% | Debt / equity | 0.00 |
| Current ratio | 1.97 | Free cash flow | -$13.78M | Analyst recommendation | none | Mean target | — |
| 52w high | $15.94 | 52w low | $1.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$6.8M | -$17.8M | -$13.4M | -$4.9M | -$4.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.2M | -$17.6M | -$6.5M | -$4.5M | -$4.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$34.7M | -$16.8M | -$18.5M | -$17.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$17.9M | -$15.1M | -$18.5M | -$17.6M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
Price (daily)
Full chart · RSI · MACD · patternsRNAZ · daily-3.4% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin